Medite Cancer Diagnostics Inc
Medite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controll… Read more
Medite Cancer Diagnostics Inc (MDIT) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2018: -0.128x
Based on the latest financial reports, Medite Cancer Diagnostics Inc (MDIT) has a cash flow conversion efficiency ratio of -0.128x as of September 2018.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-821.00K) by net assets ($6.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Medite Cancer Diagnostics Inc - Cash Flow Conversion Efficiency Trend (2013–2017)
This chart illustrates how Medite Cancer Diagnostics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Medite Cancer Diagnostics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medite Cancer Diagnostics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Live Motion Games S.A.
WAR:LMG
|
N/A |
|
Thanh Nam Group JSC
VN:TNI
|
N/A |
|
Kelyniam Global Inc
PINK:KLYG
|
-0.142x |
|
Lanka Walltiles PLC
CM:LWLN0000
|
N/A |
|
MYDECINE INNOVAT.GRP
F:0NF0
|
N/A |
|
Vimeco JSC
VN:VMC
|
N/A |
|
Northern Bear Plc
LSE:NTBR
|
0.121x |
|
ENWAVE (E4U.SG)
STU:E4U
|
0.070x |
Annual Cash Flow Conversion Efficiency for Medite Cancer Diagnostics Inc (2013–2017)
The table below shows the annual cash flow conversion efficiency of Medite Cancer Diagnostics Inc from 2013 to 2017.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2017-12-31 | $5.78 Million | $-2.58 Million | -0.448x | -228.14% |
| 2016-12-31 | $8.00 Million | $-1.09 Million | -0.136x | -222.25% |
| 2015-12-31 | $9.17 Million | $-388.00K | -0.042x | +59.95% |
| 2014-12-31 | $8.43 Million | $-891.00K | -0.106x | -211.75% |
| 2013-12-31 | $-4.27 Million | $-404.00K | 0.095x | -- |